QuantHealth, an AI-driven clinical trial design firm, has secured $15M in Series A funding led by Pitango HealthTech and Bertelsmann Investments. With a total raise of $20M, the Israeli company offers an AI-powered clinical simulator to optimize trial design by predicting treatment responses. Oklahoma-based PatchRx, a medication management platform, received $8M in Series A funding. Singapore’s Neurpowyzer focused on brain health technology, raised $2.1M in seed funding. These investments will drive product development, expansion, and innovative healthcare solutions in clinical trials, medication adherence, and brain health assessment.
QuantHealth, an AI-powered clinical trial design firm, has successfully secured $15 million in a Series A funding round, co-led by Pitango HealthTech and Bertelsmann Investments. This achievement adds to their total funding of $20 million. Operating from Israel and recently extending its presence to the U.S., QuantHealth offers the Clinical-Simulator, an AI-driven tool that forecasts an individual’s treatment response in clinical trials, optimizing trial design.
With these newly acquired funds, the company plans to bolster product development, expand its platform, diversify its commercial offerings, and explore applications beyond clinical trials, encompassing early-stage research, development, and regulatory support. Thorsten Wirkes from Bertelsmann Investments expressed excitement about co-investing with Pitango and supporting QuantHealth’s remarkable AI technologies, which have demonstrated substantial cost savings for pharmaceutical companies and accelerated patient access to treatments.
In Oklahoma, PatchRx, a medication management platform, has successfully secured $8 million in Series A funding, augmenting their total funding to $15 million. Atento Capital spearheaded this round, alongside Cortado Ventures, Vast Ventures, Plains VC, and Forum Ventures.
PatchRx introduces a smart pill bottle that employs data to enhance medication adherence. The infusion of capital will empower the company to extend its nationwide presence. The CEO of PatchRx, Aertker, emphasized their patient-centric focus, aiming to pioneer technology that ensures patient well-being and advances patient care by providing tools and insights to healthcare providers.
Singapore-based Neurpowyzer, dedicated to brain health and leveraging technology to mitigate brain decline, has added $2.1 million to its oversubscribed seed funding, amassing a total of $3.3 million. Jungle Ventures and Peak XV’s Surge co-led the funding round, supplemented by investments from angel backers Ab Gaur, Khoo Boon Hui, and Rob F Jablonski.
Neurpowyzer’s flagship product, the Digital Brain Function Screen, an online assessment tool, evaluates early brain decline potential by scrutinizing immediate memory, working memory, attention, and executive function. The seed funding will facilitate product development expansion across Southeast Asia and India, underscoring the company’s commitment to advancing brain health through innovative technological solutions.
